Megalis
Designed to support long-term erectile capability to manage performance concerns and alleviate pelvic vascular tension.
- Category
- Erectile Dysfunction
- Active ingredient
- Tadalafil
- Route
- Oral use
- Form
- Tablet
- Strengths
- 20mg
Prescription and consultation requirements for Megalis vary by destination and are determined by the fulfilment partner.
Megalis details
- Condition
- Erectile Dysfunction
- Alternative names
- tadalafil
- Therapeutic class
- Phosphodiesterase-5 Inhibitor
- Pharmacological class
- PDE5 Inhibitor
- Known off-label uses
- benign prostatic hyperplasia
- Contraindications
- organic nitrates; severe hepatic or renal impairment
- Minor side effects
- headache; dyspepsia; myalgia
- Moderate side effects
- nasal congestion; back pain; flushing
- Serious side effects
- priapism, requires immediate medical attention
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Macleods Pharmaceuticals Ltd
- Onset Time
- 30–45 minutes
- Duration
- 36 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Nitrates; Alpha Blockers; Ketoconazole
- Age restrictions
- Approved for adult men.
- Pregnancy and breastfeeding
- TGA Category B: Not indicated for females. Breastfeeding: Not applicable.
Patient summary
designed to support long-term erectile capability to manage performance concerns and alleviate pelvic vascular tension.
Mechanism of action
Inhibits phosphodiesterase-5 to preserve localised cGMP, relaxing pelvic arterial walls to promote structural blood filling.